Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease

被引：6

作者：

Antoniu, Sabina A. ^{[1
]}

机构：

[1] Gr T Popa Univ Med & Pharm Iasi, Dept Internal Med 2 Pulm Dis, Pulm Dis Univ Hosp, Iasi 700115, Romania

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2010年 / 10卷 / 02期

关键词：

chronic obstructive pulmonary disease; health-related quality of life; inhaled therapies; long-term effects; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; COPD; SALMETEROL; TIOTROPIUM; EFFICACY; FORMOTEROL; OUTCOMES; DETERIORATION; BUDESONIDE;

D O I：

10.1586/ERP.10.11

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

100404 [儿少卫生与妇幼保健学];

摘要：

In chronic obstructive pulmonary disease (COPD) health-related quality-of-life (HRQoL)/health status improvement is included among the management goals. This can be achieved, among other measures, with inhaled therapies, which, in this disease, are used alone or combined in a step-up approach based on disease severity. As COPD is a chronic disease, the long-term effects of inhaled therapies on various disease outcome measures, such as symptoms, lung function, morbidity or HRQoL, are more relevant for accessing clinical efficacy. This review discusses briefly the HRQoL assessment tools in COPD and analyses the effects of inhaled therapies on HRQoL in stable COPD.

引用

页码：155 / 162

页数：8

共 45 条

[1]

[Anonymous], 1997, Chest, V112, P1514

[2]

[Anonymous], 2009, GLOB STRAT DIAGN MAN

[3]

[Anonymous], COCHRANE DATABASE SY

[4]

Antoniu S, 2009, EUR RESP J S53, V34, p606s

[5]

Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis [J].

Barr, R. G. ;

Bourbeau, J. ;

Camargo, C. A. ;

Ram, F. S. F. .

THORAX, 2006, 61 (10) :854-862

[6]

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease [J].

Brightling, CE ;

McKenna, S ;

Hargadon, B ;

Birring, S ;

Green, R ;

Siva, R ;

Berry, M ;

Parker, D ;

Monteiro, W ;

Pavord, ID ;

Bradding, P .

THORAX, 2005, 60 (03) :193-198

[7]

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD [J].

Brusasco, V ;

Hodder, R ;

Miravitlles, M ;

Korducki, L ;

Towse, L ;

Kesten, S .

THORAX, 2003, 58 (05) :399-404

[8]

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].

Burge, PS ;

Calverley, PMA ;

Jones, PW ;

Spencer, S ;

Anderson, JA ;

Maslen, TK .

BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303

[9]

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].

Calverley, P ;

Pauwels, R ;

Vestbo, J ;

Jones, P ;

Pride, N ;

Gulsvik, A ;

Anderson, J ;

Maden, C .

LANCET, 2003, 361 (9356) :449-456

[10]

One-year treatment with mometasone furoate in chronic obstructive pulmonary disease [J].

Calverley, Peter M. A. ;

Rennard, Stephen ;

Nelson, Harold S. ;

Karpel, Jill P. ;

Abbate, Eduardo H. ;

Stryszak, Paul ;

Staudinger, Heribert .

RESPIRATORY RESEARCH, 2008, 9 (1)

← 1 2 3 4 5 →